• argenx completed its acquisition of Forte Biosciences via a cash tender offer and subsequent merger.
• Forte shareholders received USD 77 per share in cash, subject to applicable tax withholding.
• At tender expiration on Aug. 26, 2026, 19,894,879 shares were tendered; ownership reached about 87.13% including argenx holdings.
• Forte became a wholly owned subsidiary; its stock will no longer trade on Nasdaq.
• Deal adds Forte’s FB102, an anti-CD122 antibody with clinical data in vitiligo and celiac disease, to argenx’s immunology pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270850PRIMZONEFULLFEED1001259677) on August 27, 2026, and is solely responsible for the information contained therein.